Apollo Hospitals Enterprise (APOLLOHOSP)

Loading page…

Apollo Hospitals Enterprise (APOLLOHOSP) · mywealthgrid

About

India's largest private hospital chain with ₹7,043.5 Cr consolidated quarterly revenue (Q2 FY27) and expanding into diagnostics and digital health. Market-cap ₹1,28,276.79 Cr with ROE of 21.95% and 1-year return of 24.41%, reflecting investor confidence in scale and profitability, though valuation is stretched at PE 61.39.

Founded: 1983
Face value: ₹5

Market cap

₹1,16,960 Cr

P/E

56.0×

P/B

12.3×

Dividend yield

0.4%

ROE

21.9%

ROCE

19.4%

Debt / equity

0.6

OPM

14.9%

EPS (TTM)

₹145.3

Book value

₹659.3

52-week high

—

52-week low

Key insights

Company research notes and source-linked reviews

Key risks

Valuation risk: PE 61.39 leaves minimal margin of safety if earnings growth slows or disappoints.

Margin gap: Consolidated operating margins (14.9–15.5%) significantly lag standalone margins (24–25%), raising questions about profitability of expansion segments.

Foreign capital concentration: FII holding at 41.5% versus promoter stake at 28% creates exposure to international fund flow volatility.

Regulatory pressure: Verify impact of healthcare pricing regulation, reimbursement policy changes, and labor cost mandates on consolidated margins.

Generated analysis · source review pending

Growth drivers

Revenue scaling: consolidated revenue grew 11.7% year-on-year (₹6,303.5 Cr Sep 2025 to ₹7,043.5 Cr Jun 2026) with profit growth accelerating to 23.5%.

Diagnostic and digital health expansion cited in description—verify market opportunity, rollout status, revenue contribution, and margin profile.

Standalone segment stable at 24–25% OPM over 9 months (Dec 2025 25.11%, Mar 2026 24.42%, Jun 2026 24.71%) provides high-margin operational base.

ROE of 21.95% signals efficient capital deployment; verify reinvestment rate and capex allocation strategy.

Generated analysis · source review pending

2,528 historical price candles were omitted because the exchange source has not been verified.

₹8,133.5-6.1%1Y

Quick read

rule-based

Pros

+Strong return on equity of 18.2% (3-yr avg)
+Profit CAGR of 66.8% over the last 5 years
+Revenue CAGR of 19% over the last 5 years

Cons

−Trading at 12.3× book value

Research score

Structured signal from quality, growth, valuation and momentum.

49/100

Business quality: 52
Growth: 86
Valuation: 8

Revenue & net profit

₹ crore, by fiscal year

RevenuePAT

Margins

% of revenue, by fiscal year

OPMPAT margin

Peers

Comparable companies from the narrowest available industry classification.

Part ofNIFTY 50 NIFTY 100 NIFTY 200 NIFTY 500 NIFTY TOTAL MARKET

Screen this industry Compare top 5 side-by-side

Company	Mkt Cap	EV	Revenue	EBITDA	OPM	PAT	NPM	ROCE	ROE	WC Days
Sun Pharmaceutical IndustriesSUNPHARMASUNPHARMA	₹4,32,240 Cr	₹4,36,322 Cr	₹59,911 Cr	₹17,847 Cr	30.3%	₹12,096 Cr	19.7%	20.9%	14.7%	228
Divi's LaboratoriesDIVISLABDIVISLAB	₹2,45,561 Cr	₹2,45,561 Cr	₹11,230 Cr	₹3,967 Cr	32.6%	₹2,925 Cr	24.3%	20.8%	16.2%	348
Torrent Pharmaceuticals LimitedTORNTPHARMTORNTPHARM	₹1,61,325 Cr	₹1,76,123 Cr	₹15,723 Cr	₹5,191 Cr	32.6%	₹2,181 Cr	15.3%	14.5%	27.1%	163
Apollo Hospitals EnterpriseAPOLLOHOSPAPOLLOHOSP	₹1,16,960 Cr	₹1,22,618 Cr	₹26,430 Cr	₹4,010 Cr	14.9%	₹2,090 Cr	7.9%	19.4%	21.9%	3
Zydus Lifesciences LimitedZYDUSLIFEZYDUSLIFE	₹1,14,284 Cr	₹1,26,053 Cr	₹28,592 Cr	₹8,316 Cr	31.2%	₹4,513 Cr	18.9%	23.4%	19.7%	212
CiplaCIPLACIPLA	₹1,08,864 Cr	₹1,09,122 Cr	₹28,324 Cr	₹5,297 Cr	20.9%	₹3,371 Cr	13.7%	16.5%	11.8%	202
Laurus Labs LimitedLAURUSLABSLAURUSLABS	₹1,07,176 Cr	₹1,09,573 Cr	₹7,270 Cr	₹2,034 Cr	26.1%	₹1,093 Cr	13.1%	21.3%	18.2%	263
Mankind Pharma LimitedMANKINDMANKIND	₹1,04,696 Cr	₹1,11,007 Cr	₹14,738 Cr	₹3,827 Cr	25.3%	₹2,068 Cr	13.6%	14.2%	12.5%	117
Dr. Reddy's LaboratoriesDRREDDYDRREDDY	₹1,00,682 Cr	₹1,06,975 Cr	₹33,228 Cr	₹5,140 Cr	19.2%	₹3,222 Cr	12.3%	14.8%	11.7%	247
Aurobindo Pharma LimitedAUROPHARMAAUROPHARMA	₹97,389 Cr	₹1,05,065 Cr	₹34,935 Cr	₹7,085 Cr	20.3%	₹3,713 Cr	10.4%	14.7%	9.9%	252
Lupin LimitedLUPINLUPIN	₹92,866 Cr	₹98,777 Cr	₹29,967 Cr	₹9,538 Cr	31.5%	₹5,529 Cr	19.2%	34.2%	26.9%	181
Max Healthcare Institute LimitedMAXHEALTHMAXHEALTH	₹91,573 Cr	₹95,052 Cr	₹8,712 Cr	₹2,318 Cr	26.8%	₹1,457 Cr	17.2%	13.8%	14.3%	-110

Loading peers…

Financials

Reported profit and loss, balance sheet, cash flow and growth history.

Annual Quarterly

Consolidated Standalone

Consolidated figures · ₹ crore

₹ Cr	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	8,243	9,617	11,247	10,560	14,663	16,612	19,059	21,794	25,229
COGS	4,111	4,733	5,499	5,684	7,573	8,574	9,806	11,310	13,076
Gross profit	4,133	4,885	5,748	4,876	7,089	8,038	9,254	10,484	12,153
	3,339	3,821	4,164	3,738	4,897	6,032	6,845	7,429	8,339
	793	1,064	1,584	1,138	2,192	2,006	2,409	3,055	3,814
OPM %	9.6%	11.1%	14.1%	10.8%	15%	12.1%	12.6%	14%	15.1%
Depreciation	359	396	620	573	601	615	687	758	876
Interest	295	327	533	449	379	381	449	459	450
	32	31	225	106	372	90	108	200	172
Profit before tax	171	—	657	221	1,585	1,101	1,381	2,039	2,661
Tax	112	173	225	85	477	256	446	534	658
Tax %	65.3%	—	34.3%	38.2%	30.1%	23.3%	32.3%	26.2%	24.7%
	60	199	432	137	1,108	845	935	1,505	2,003
PAT margin %	0.7%	2.1%	3.8%	1.3%	7.6%	5.1%	4.9%	6.9%	7.9%
EPS (₹)	—	—	32.7	10.7	73.4	57	62.5	100.6	135
EPS adjusted (₹)	8.4	17	32.7	10.5	73.4	57	62.5	100.6	135
	—	—	18.3%	27.9%	16%	26.3%	25.6%	18.9%	14.8%
Annual report	Annual report for Mar 2018	Annual report for Mar 2019	Annual report for Mar 2020	Annual report for Mar 2021	Annual report for Mar 2022	Annual report for Mar 2023	Annual report for Mar 2024	Annual report for Mar 2025	Annual report for Mar 2026

₹ Cr	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity capital	70	70	70	70	70	72	72	72	72	72	72
Reserves	3,384	3,240	3,182	3,264	3,269	4,531	5,551	6,125	6,864	8,140	9,408
Minority interest	—	128	132	135	131	200	254	334	385	441	494
	2,478	3,024	3,303	3,450	3,350	2,859	2,636	2,710	3,162	5,275	5,659
	1,756	1,657	1,926	2,264	4,519	3,755	4,679	5,186	6,271	6,729	6,564
Total equity & liabilities	7,687	8,119	8,613	9,183	11,338	11,417	13,192	14,428	16,753	20,657	22,197
	3,613	4,583	4,766	4,975	5,779	5,789	7,192	8,516	9,661	10,985	12,269
CWIP	596	347	712	822	209	212	44	602	845	771	992
Investments	270	106	58	69	440	1,348	784	578	990	2,490	2,181
	3,209	3,083	3,077	3,317	4,910	4,068	5,172	4,733	5,258	6,411	6,755
Total assets	7,687	8,119	8,613	9,183	11,338	11,417	13,192	14,428	16,753	20,657	22,197

Segment results

As reported in NSE results XBRL. Segment result is before tax and finance costs. ROCE uses that annual result divided by segment assets less liabilities.

Source XBRL ↗

Latest reported period · 31 Mar 2026 · ₹ crore

Segment	Revenue	Result	Assets	Liabilities	Capital employed	ROCE %
Healthcare services	12,750.1	2,430.3	14,486.2	3,935.7	10,550.5	23.03
Digital health & pharmacy distribution	10,808.1	398.7

Loading financials…

Ratios

Annual operating, return, leverage and working-capital ratios.

Consolidated Standalone

Consolidated figures

Ratio	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	50.8%	51.1%	46.2%	48.3%	48.4%	48.6%	48.1%	48.2%
EBITDA margin %	11.1%	14.1%	10.8%	14.9%	12.3%	12.5%	13.9%	14.9%
EBIT margin %	6.9%	8.6%	5.3%	10.8%	8.6%	8.9%	10.4%	11.5%
PAT margin %	2.1%	3.8%	1.3%	7.6%	5.1%	4.9%	6.9%	7.9%
Working capital
Receivable days	39	33	46	44	49	48	51	50
Inventory days	45	49	16	21	17	17	16	15
Payable days	1	60	74	79	82	88	72	63
NWC days	83	22	-12	-14	-16	-23	-6	3
Leverage
Current ratio	1.17	1.13	1.79	1.73	1.3	1.13	1.54	1.06
Debt to EBITDA	3.24	2.11	2.51	1.21	1.32	1.32	1.75	1.5
Debt to equity	1.04	1	0.62	0.47	0.44	0.46	0.64	0.6
Interest coverage	2.1	1.9	1.4	4.4	4	4	5.4	6.9
Asset turnover	1.05	0.99	0.92	1.11	1.15	1.14	1.06	1.14
Return ratios
Return on assets %	2.2%	3.8%	1.2%	8.4%	5.9%	5.6%	7.3%	9%
Return on capital employed %	9.8%	12.3%	6.6%	16.5%	13.9%	15.6%	17.5%	19.4%
Return on equity %	6%	12.9%	3%	19.7%	13.6%	13.5%	18.3%	21.1%

Derived from reported annual statements. ROCE uses EBIT over capital employed (total assets less current liabilities). Day counts average the opening and closing balance; receivables turn on revenue, inventory and payables on cost of goods sold.

Loading ratios…

Shareholding

Quarterly ownership, named holders, insider transactions and disclosed deals.

Quarterly Annual

Every quarter filed · % of equity

Holder (%)	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	29.33%	29.33%	29.33%	29.33%	29.33%	29.33%	29.34%	29.34%	28.02%	28.02%	28.02%	28.02%
	46.15%	46.25%	45.63%	43.92%	45.37%	45.27%	42.74%	43.49%	44.2%	43.54%	42.62%	41.5%
	18.6%	18.87%	19.55%	21.14%	19.95%	19.98%	22.29%	21.34%	21.12%	21.51%	22.76%	23.72%
	0%	0%	0%	0%	0%	0%	0%	0%	0.23%	0.23%	0.23%	0.23%
	5.92%	5.55%	5.49%	5.61%	5.35%	5.42%	5.63%	5.83%	6.43%	6.7%	6.37%	6.53%
No. of shareholders	—	—	—	—	—	—	—	—	1,60,556	1,78,648	1,74,610	1,74,281

Loading shareholding…

F&O

Current futures and options contracts with compact option-chain pages.

End of day 30 Sept 2026 · underlying ₹8,165.2 · volume and open interest in contracts

3

Expiry	Close	Chg	% Chg	Settlement	Open interest	Change in OI	Volume	Lot size
27 Oct 2026	₹8,128.0	-611	-7%	₹8,128.0	16,289	-421	11,341	125
23 Nov 2026	₹8,159.0	-619	-7.1%	₹8,159.0	2,152	+218	445	125
29 Dec 2026	₹8,212.0	-576	-6.6%	₹8,212.0	10	+10	20	125

Open the chart icon on a row for that contract's close over 103 stored sessions, with open interest as bars beneath it.

32

27 Oct 2026 23 Nov 2026 29 Dec 2026

Calls				Strike	Puts
OI	Chg OI	Volume	LTP	—	LTP	Volume	Chg OI	OI
0	0	0	₹0.0	7,000

Loading f&o…

Fund holders

Mutual-fund schemes that disclosed a holding in the company.

Portfolio month

Schemes holding

214

across 24 fund houses

Held by these funds

9.87%

of the company's equity

All mutual funds

17.33%

shareholding pattern, Jun 2026

Portfolios as of

August 2026

compared with July 2026

214 schemes · 24 fund houses

		Shares
Nifty 50 ETF	SBI Mutual Fund	19.96 L	1,776.25	0.83%	1.388%	+10,494
Large Cap Fund	Axis Mutual Fund	10.41 L	926.02	2.95%	0.724%	-0
Focused Fund	Axis Mutual Fund	6.68 L	594.53	5.2%	0.465%	-0
ETF NIFTY 50 BEES	Nippon India Mutual Fund	6.26 L	557.34	0.83%	0.436%	+12,501
Flexicap Fund	SBI Mutual Fund	5.66 L	503.43	2.17%	0.393%	-0
Franklin India Flexi Cap Fund ( Formerly known as Franklin India Equity Fund) ^NEW	Franklin Templeton Mutual Fund	5.62 L	500.2	2.58%	0.391%	—
PHARMA FUND	Nippon India Mutual Fund	5.49 L	488.35	5.15%	0.382%	-0
(Investment Manager for Motilal Oswal Mutual Fund)	Motilal Oswal Mutual Fund	4.75 L	422.68	2.1%	0.33%	-0

1–8 of 214

1 / 27

Loading fund holders…

Documents

Annual reports, exchange filings, offer documents, ratings and earnings-call material.

Announcements

Loading documents…

Events

Upcoming dates and the company’s corporate-action history.

Loading events…

Announcements

Latest exchange announcements, filings and downloadable documents.

1 month 3 months 6 months 1 year All

89 announcementsExport CSV

3 Sept 2026, 6:00 pmCompany Update

Notice For Transfer Of Shares To IEPF

General PDF

Loading announcements…

Ratio	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	50.8%	51.1%	46.2%	48.3%	48.4%	48.6%	48.1%	48.2%
EBITDA margin %	11.1%	14.1%	10.8%	14.9%	12.3%	12.5%	13.9%	14.9%
EBIT margin %	6.9%	8.6%	5.3%	10.8%	8.6%	8.9%	10.4%	11.5%
PAT margin %	2.1%	3.8%	1.3%	7.6%	5.1%	4.9%	6.9%	7.9%
Working capital
Receivable days	39	33	46	44	49	48	51	50
Inventory days	45	49	16	21	17	17	16	15
Payable days	1	60	74	79	82	88	72	63
NWC days	83	22	-12	-14	-16	-23	-6	3
Leverage
Current ratio	1.17	1.13	1.79	1.73	1.3	1.13	1.54	1.06
Debt to EBITDA	3.24	2.11	2.51	1.21	1.32	1.32	1.75	1.5
Debt to equity	1.04	1	0.62	0.47	0.44	0.46	0.64	0.6
Interest coverage	2.1	1.9	1.4	4.4	4	4	5.4	6.9
Asset turnover	1.05	0.99	0.92	1.11	1.15	1.14	1.06	1.14
Return ratios
Return on assets %	2.2%	3.8%	1.2%	8.4%	5.9%	5.6%	7.3%	9%
Return on capital employed %	9.8%	12.3%	6.6%	16.5%	13.9%	15.6%	17.5%	19.4%
Return on equity %	6%	12.9%	3%	19.7%	13.6%	13.5%	18.3%	21.1%

Calls	Strike	Puts
0	0	0	₹0.0	7,000

7 disclosures

Person	Deal	Shares	Value	Holding	Filed
PCR INVESTMENTS LIMITEDPromoters	Pledge RevokeRevokation of Pledge	23,00,000	₹180.71 cr	18.93% → 18.93%	17 Oct 20257(2)
K VISHWESHWAR REDDYPromoters	PledgePledge Creation	70,000	₹52.11 cr	1.10% → 1.10%	30 Sept 20257(2)
SUNEETA REDDYPromoters	Pledge RevokeRevokation of Pledge	1,75,000	₹137.89 cr	2.04% → 2.04%	13 Sept 20257(2)
K VISHWESHWAR REDDYPromoters	Pledge RevokeRevokation of Pledge	2,77,946	₹219.62 cr	1.10% → 1.10%	10 Sept 20257(2)
SUNEETA REDDYPromoters	Pledge RevokeRevokation of Pledge	5,75,000	₹444.82 cr	2.04% → 2.04%	5 Sept 20257(2)
PCR INVESTMENTS LIMITEDPromoters	PledgePledge Creation	1,10,000	₹83.71 cr	1.10% → 1.10%	30 Aug 20257(2)
SUNEETA REDDYPromoters	SellMarket Sale	18,97,239	₹1,483.42 cr	3.36% → 2.04%	26 Aug 20257(2)

Disclosed under SEBI’s insider-trading regulations, which require a filing only above ₹10 lakh in a quarter — smaller dealings are in no disclosure. Holdings are the filer’s own percentages, not recomputed.

112 deals · 31 Aug 2021 – 19 Nov 2025

Date	Client	Type	Venue	Side	Quantity	Price	Value
19 Nov 2025	BOFA SECURITIES EUROPE SA	Block	NSE	Sell	59,584	₹7,312.00	₹43.57 Cr
19 Nov 2025	KADENSA MASTER FUND	Block	NSE	Buy	59,584	₹7,312.00	₹43.57 Cr
10 Nov 2025	GOLDMAN SACHS BANK EUROPESE-ODI	Block	NSE	Sell	92,363	₹7,474.00	₹69.03 Cr
10 Nov 2025	BOFA SECURITIES EUROPE SA	Block	NSE	Buy	92,363	₹7,474.00	₹69.03 Cr
17 Sept 2025	GOLDMAN SACHS (SINGAPORE) PTE - ODI	Block	NSE	Sell	52,098	₹7,852.50	₹40.91 Cr
17 Sept 2025	GOLDMAN SACHS BANK EUROPE SE - ODI	Block	NSE	Buy	52,098	₹7,852.50	₹40.91 Cr
15 Sept 2025	GOLDMAN SACHS (SINGAPORE) PTE - ODI	Block	NSE	Sell	40,265	₹7,874.50	₹31.71 Cr
15 Sept 2025	GOLDMAN SACHS BANK EUROPE SE - ODI	Block	NSE	Buy	40,265	₹7,874.50	₹31.71 Cr
9 Sept 2025	GOLDMAN SACHS (SINGAPORE) PTE - ODI	Block	NSE	Sell	43,031	₹7,786.50	₹33.51 Cr
9 Sept 2025	GOLDMAN SACHS BANK EUROPE SE - ODI	Block	NSE	Buy	43,031	₹7,786.50	₹33.51 Cr

1–10 of 112

1 / 12

Bulk deals are a client trading over 0.5% of the equity in a session, aggregated across their trades; block deals are single negotiated trades in the exchange’s block window. Each is reported by the exchange it was crossed on, so NSE and BSE rows are separate trades rather than the same trade twice.

Date	Category	Subject	Filing
3 Sept 2026, 6:00 pm	Company Update General	Notice For Transfer Of Shares To IEPF	PDF
28 Aug 2026, 3:25 pm	Others Reg. 34 (1) Annual Report	Reg. 34 (1) Annual Report.	PDF
25 Aug 2026, 6:03 pm	Company Update General	Summary Of Proceedings Of AGM And Voting Results	PDF
25 Aug 2026, 5:54 pm	AGM/EGM AGM	Shareholder Meeting / Postal Ballot-Scrutinizer''s Report	PDF
25 Aug 2026, 5:52 pm	AGM/EGM AGM	Shareholder Meeting / Postal Ballot-Outcome of AGM	PDF
19 Aug 2026, 5:57 pm	Company Update Analyst / Investor Meet	Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome	PDF
13 Aug 2026, 6:34 pm	Company Update Analyst / Investor Meet	Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome	PDF
12 Aug 2026, 9:52 pm	Company Update Investor Presentation	Announcement under Regulation 30 (LODR)-Investor Presentation	PDF

₹ Cr	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	423	632	539	905	1,293	1,273	1,616	1,377	1,920	2,136	2,856
	-684	-804	-378	-711	-289	-872	-791	-857	-1,537	-3,381	-2,148
	272	130	-106	-215	-910	-340	-768	-633	-311	1,317	-478
Net cash flow	12	—	54	-20	95	61	57	-113	72	73	230
Free cash flow	-408	54	21	226	780	978	958	249	784	424	894
CFO / Operating profit %	—	—	67.9%	85.1%	81.5%	112%	73.9%	67.2%	80.3%	70.7%	75.8%

Apollo Hospitals Enterprise

About

Key insights

Key risks

Growth drivers

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Segment results

Ratios

Shareholding

F&O

3

32

Fund holders

Documents

Announcements

Events

Announcements

3

32

Announcements

Annual reports

Credit ratings

25

1

1

Segment results

Compounded sales growth

Compounded profit growth

Return on equity

Digital Health & Pharmacy Distribution · revenue

Apollo Hospitals Enterprise

About

Key insights

Key risks

Growth drivers

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Profit & loss

Balance sheet

Segment results

Ratios

Ratio timeline

Shareholding

Quarterly record

F&O

Futures3

Option chain32

Fund holders

Documents

Announcements

Events

Announcements

Ratio timeline

Futures3

Option chain32

Announcements

Quarterly record

Annual reports

Credit ratings

Dividends25

Board meetings1

Stock splits1

Insider dealing

Bulk & block deals

Board and management

Profit & loss

Balance sheet

Segment results

Cash flow

Compounded returns

Compounded sales growth

Compounded profit growth

Return on equity

Digital Health & Pharmacy Distribution · revenue

3

32

3

32

25

1

1